Laboratory Products
Rhabdovirus-free Insect Platform for Viral Vaccines and Gene Therapy Development Announced
Oct 10 2018
Merck is collaborating with GlycoBac LLC to offer a Sf-9 insect cell line. GlycoBac’s development of a proven rhabdovirus-negative (RVN) cell line enables Merck to offer the first Sf-9 platform combining a rhabdovirus-free insect cell line with a corresponding, chemically defined cell culture medium. This will be the first non-mammalian cell line in Merck’s cell culture portfolio, allowing customers worldwide access to a safer, high-performing vehicle for recombinant protein expression, Virus-like Particle vaccines and Adeno Associated Virus based gene therapy production.
The insect cell line will provide time and cost savings in analytics and validation, and speed development by circumventing process steps normally required to prove elimination of rhabdovirus. In addition, Merck’s chemically defined hydrolysate-free medium addresses consistency concerns while also reducing overall variability in growth and productivity.
Merck’s insect cell line extends the company’s upstream offerings for viral vaccine and gene therapy applications, complementing Merck’s well-known mammalian CHOZN® platform. Collectively, Merck’s upstream and downstream solutions now constitute a robust portfolio for mAb, vaccine and virus production.
The Merck Sf-RVN platform will be available from a cGMP cell bank to purchase in 2019.
Digital Edition
ILM 49.5 July
July 2024
Chromatography Articles - Understanding PFAS: Analysis and Implications Mass Spectrometry & Spectroscopy Articles - MS detection of Alzheimer’s blood-based biomarkers LIMS - Essent...
View all digital editions
Events
ACS National Meeting - Fall 2024
Aug 18 2024 Denver, CO, USA
Aug 25 2024 Copenhagen, Denmark
Aug 28 2024 Phnom Penh, Cambodia
Sep 04 2024 Chiba, Tokyo, Japan
Sep 04 2024 University of Warwick, Coventry, UK